AllianceBernstein’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $738K | Sell |
17,233
-1,660
| -9% | -$55.8K | ﹤0.01% | 2458 |
|
|
2025
Q4 | $809K | Sell |
18,893
-14,240
| -43% | -$537K | ﹤0.01% | 2438 |
|
|
2025
Q3 | $939K | Buy |
33,133
+1,660
| +5% | +$49.7K | ﹤0.01% | 2377 |
|
|
2025
Q2 | $589K | Hold |
31,473
| – | – | ﹤0.01% | 2543 |
|
|
2025
Q1 | $566K | Hold |
31,473
| – | – | ﹤0.01% | 2506 |
|
|
2024
Q4 | $529K | Hold |
31,473
| – | – | ﹤0.01% | 2612 |
|
|
2024
Q3 | $509K | Hold |
31,473
| – | – | ﹤0.01% | 2656 |
|
|
2024
Q2 | $259K | Hold |
31,473
| – | – | ﹤0.01% | 2968 |
|
|
2024
Q1 | $466K | Hold |
31,473
| – | – | ﹤0.01% | 2611 |
|
|
2023
Q4 | $456K | Hold |
31,473
| – | – | ﹤0.01% | 2655 |
|
|
2023
Q3 | $340K | Sell |
31,473
-1,225
| -4% | -$14.7K | ﹤0.01% | 2755 |
|
|
2023
Q2 | $422K | Buy |
32,698
+1,684
| +5% | +$22.8K | ﹤0.01% | 2728 |
|
|
2023
Q1 | $409K | Hold |
31,014
| – | – | ﹤0.01% | 2653 |
|
|
2022
Q4 | $465K | Buy |
31,014
+1,570
| +5% | +$14.4K | ﹤0.01% | 2673 |
|
|
2022
Q3 | $347K | Hold |
29,444
| – | – | ﹤0.01% | 2801 |
|
|
2022
Q2 | $333K | Buy |
29,444
+13,610
| +86% | +$273K | ﹤0.01% | 2841 |
|
|
2022
Q1 | $473K | Buy |
15,834
+60
| +0.4% | +$1.62K | ﹤0.01% | 2709 |
|
|
2021
Q4 | $418K | Hold |
15,774
| – | – | ﹤0.01% | 2814 |
|
|
2021
Q3 | $573K | Hold |
15,774
| – | – | ﹤0.01% | 2708 |
|
|
2021
Q2 | $685K | Buy |
15,774
+2,340
| +17% | +$88.3K | ﹤0.01% | 2682 |
|
|
2021
Q1 | $459K | Sell |
13,434
-2,940
| -18% | -$116K | ﹤0.01% | 2693 |
|
|
2020
Q4 | $573K | Buy |
16,374
+1,340
| +9% | +$38.8K | ﹤0.01% | 2527 |
|
|
2020
Q3 | $361K | Sell |
15,034
-8,590
| -36% | -$211K | ﹤0.01% | 2713 |
|
|
2020
Q2 | $432K | Buy |
23,624
+2,420
| +11% | +$43.5K | ﹤0.01% | 2702 |
|
|
2020
Q1 | $331K | Hold |
21,204
| – | – | ﹤0.01% | 2570 |
|
|
2019
Q4 | $454K | Hold |
21,204
| – | – | ﹤0.01% | 2585 |
|
|
2019
Q3 | $397K | Buy |
21,204
+870
| +4% | +$18K | ﹤0.01% | 2674 |
|
|
2019
Q2 | $531K | Buy |
20,334
+1,130
| +6% | +$25.5K | ﹤0.01% | 2577 |
|
|
2019
Q1 | $494K | Sell |
19,204
-115,000
| -86% | -$2.63M | ﹤0.01% | 2526 |
|
|
2018
Q4 | $3.09M | Hold |
134,204
| – | – | ﹤0.01% | 1576 |
|
|
2018
Q3 | $4.31M | Buy |
134,204
+17,500
| +15% | +$525K | ﹤0.01% | 1389 |
|
|
2018
Q2 | $3.3M | Buy |
116,704
+49,100
| +73% | +$1.75M | ﹤0.01% | 1555 |
|
|
2018
Q1 | $2.39M | Buy |
67,604
+17,300
| +34% | +$692K | ﹤0.01% | 1712 |
|
|
2017
Q4 | $1.95M | Buy |
50,304
+830
| +2% | +$31.6K | ﹤0.01% | 1871 |
|
|
2017
Q3 | $1.26M | Buy |
49,474
+35,000
| +242% | +$851K | ﹤0.01% | 2151 |
|
|
2017
Q2 | $395K | Buy |
14,474
+2,860
| +25% | +$78.3K | ﹤0.01% | 2698 |
|
|
2017
Q1 | $384K | Hold |
11,614
| – | – | ﹤0.01% | 2613 |
|
|
2016
Q4 | $276K | Hold |
11,614
| – | – | ﹤0.01% | 2776 |
|
|
2016
Q3 | $426K | Hold |
11,614
| – | – | ﹤0.01% | 2580 |
|
|
2016
Q2 | $259K | Buy |
11,614
+290
| +3% | +$7.21K | ﹤0.01% | 2733 |
|
|
2016
Q1 | $236K | Hold |
11,324
| – | – | ﹤0.01% | 2667 |
|
|
2015
Q4 | $343K | Sell |
11,324
-100
| -0.9% | -$3.03K | ﹤0.01% | 2581 |
|
|
2015
Q3 | $282K | Sell |
11,424
-17,948
| -61% | -$536K | ﹤0.01% | 2685 |
|
|
2015
Q2 | $943K | Buy |
29,372
+600
| +2% | +$22.9K | ﹤0.01% | 2316 |
|
|
2015
Q1 | $1.03M | Hold |
28,772
| – | – | ﹤0.01% | 2170 |
|
|
2014
Q4 | $653K | Sell |
28,772
-170
| -0.6% | -$3.44K | ﹤0.01% | 2403 |
|
|
2014
Q3 | $561K | Hold |
28,942
| – | – | ﹤0.01% | 2472 |
|
|
2014
Q2 | $1.05M | Sell |
28,942
-692
| -2% | -$23.5K | ﹤0.01% | 2222 |
|
|
2014
Q1 | $1.15M | Sell |
29,634
-26
| -0.1% | -$927 | ﹤0.01% | 2082 |
|
|
2013
Q4 | $845K | Sell |
29,660
-3,250
| -10% | -$95.4K | ﹤0.01% | 2239 |
|
|
2013
Q3 | $1.18M | Buy |
32,910
+172
| +0.5% | +$6.28K | ﹤0.01% | 2042 |
|
|
2013
Q2 | $1.09M | Buy |
+32,738
| New | +$1.48M | ﹤0.01% | 2027 |
|
Other funds holding RIGL
AC
VCM
AllianceBernstein's RIGL Position: Q1 2026 in Review
AllianceBernstein reduced its Rigel Pharmaceuticals (RIGL) stake by 8.8% in Q1 2026, selling an estimated $55.8K and leaving 17,233 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #2458.
AllianceBernstein first reported a position in RIGL in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.31M in Q3 2018. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- AllianceBernstein held 17,233 shares of Rigel Pharmaceuticals worth $738K as of Q1 2026.
- AllianceBernstein sold 1,660 Rigel Pharmaceuticals shares in Q1 2026, an estimated $55.8K.
- Rigel Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2458 holding.
- AllianceBernstein first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- AllianceBernstein's Rigel Pharmaceuticals position peaked at $4.31M in Q3 2018.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.